¼¼°èÀÇ HSV °Ë»ç ½ÃÀå : HSV À¯Çüº°, °Ëü À¯Çüº°, ¿¬·ÉÃþº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
HSV Testing Market, By HSV Type, By Type, By Sample Type, By Age Group, By Application, By End User, By Geography
»óǰÄÚµå : 1789378
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,322,000
Unprintable PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,834,000
PDF & Excel (Multi User License - Up to 7 Users) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ÃÖ´ë 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,049,000
PDF & Excel (Corporate User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

HSV °Ë»ç ½ÃÀåÀº 2025³â¿¡´Â 6¾ï 4,240¸¸ ´Þ·¯, 2032³â¿¡´Â 9¾ï 7,230¸¸ ´Þ·¯¿¡ À̸£°í, 2025-2032³â ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)Àº 6.1%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

º¸°í¼­ ¹üÀ§ º¸°í¼­ »ó¼¼
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 6¾ï 4,240¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â 6.10% 2032³â ±Ý¾× ¿¹Ãø 9¾ï 7,230¸¸ ´Þ·¯

¼¼°è HSV °Ë»ç ½ÃÀåÀº ±¤¹üÀ§ÇÑ Áø´Ü °Ë»ç »ê¾÷ Áß Áß¿äÇÑ ºÎ¹®À¸·Î, Àü ¼¼°è ¼ö¹é¸¸ ¸íÀÌ ¾Î°í ÀÖ´Â ´Ü¼ø Æ÷Áø ¹ÙÀÌ·¯½º °¨¿°À» °¨ÁöÇÏ°í ½Äº°ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. HSV °Ë»ç´Â PCR ±â¹Ý ºÐ¼®, Ç׿ø °ËÃâ °Ë»ç, Ç×ü ±â¹Ý Ç÷ûÇÐÀû °Ë»ç, ¹ÙÀÌ·¯½º ¹è¾ç ±â¼úÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ Áø´Ü ¹æ¹ýÀ» Æ÷ÇÔÇϸç, °¢°¢ ´Ù¾çÇÑ ¹Î°¨µµ¿Í ƯÀ̵µ·Î HSV-1 ¹× HSV-2 °¨¿°À» ½Äº°Çϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¼ºº´¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í, Àü ¼¼°èÀûÀ¸·Î Ç츣Æä½º °¨¿°ÀÇ À¯º´·üÀÌ Áõ°¡Çϰí, Á¶±â Áø´Ü ¹× Ä¡·á °³ÀÔ¿¡ ´ëÇÑ Á߿伺ÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀåÀÇ Á߿伺ÀÌ Å©°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü, ÀÓ»ó ½ÇÇè½Ç, ÇöÀå Áø·á °Ë»ç ½Ã¼³Àº HSV °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ´Â ÁÖ¿ä ÃÖÁ¾ »ç¿ëÀÚ¸¦ ±¸¼ºÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå »óȲÀº ½Å¼ÓÇÑ Áø´Ü °Ë»ç, Á¤È®µµ¸¦ ³ôÀÎ ºÐÀÚÁø´Ü, ¿öÅ©Ç÷οì È¿À²¼ºÀ» Çâ»ó½ÃŰ´Â ÀÚµ¿ °Ë»ç Ç÷§Æû °³¹ß µî Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀüÀ¸·Î Ư¡Áö¾îÁý´Ï´Ù. ¶ÇÇÑ, µðÁöÅÐ Çコ ¼Ö·ç¼Ç°ú ¿ø°Ý ÀÇ·á Ç÷§ÆûÀÇ ÅëÇÕÀº ƯÈ÷ ¿ø°ÝÁö³ª ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª¿¡¼­ HSV °Ë»ç¸¦ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ´Â »õ·Î¿î ±æÀ» ¿­¾îÁÖ¾ú½À´Ï´Ù. ½ÃÀåÀÇ ÁøÈ­´Â »õ·Î¿î °Ë»ç ¹æ¹ý¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ÀÇ·áºñ ÁöÃâ Áõ°¡, ±â¹Ð¼º°ú ÆíÀǼºÀÌ ³ôÀº °Ë»ç ¿É¼Ç¿¡ ´ëÇÑ È¯ÀÚ ¼±È£µµ Áõ°¡¿¡ ÀÇÇØ ´õ¿í ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°è HSV °Ë»ç ½ÃÀåÀº ´Ù¾çÇÑ ÇコÄɾî ȯ°æ¿¡¼­ ½ÃÀå È®´ë¿Í äÅ÷üÀ» ³ôÀÌ´Â ¸î °¡Áö ÁÖ¿ä ÃËÁø¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎÀº ´Ü¼ø Ç츣Æä½º ¹ÙÀÌ·¯½º °¨¿°ÀÇ Àü ¼¼°èÀû È®»ê¿¡ ±âÀÎÇϸç, WHO ÃßÁ¤¿¡ µû¸£¸é Àü ¼¼°è 50¼¼ ÀÌÇÏ Àα¸ Áß 37¾ï ¸í ÀÌ»óÀÌ HSV-1 °¨¿°À» ¾Î°í ÀÖ°í, 15-49¼¼ Àα¸ Áß 4¾ï 9,100¸¸ ¸íÀÌ HSV-2 °¨¿°À» ¾Î°í ÀÖ¾î Á¤È®ÇÑ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä´Â ¸Å¿ì Å®´Ï´Ù. ¼Ö·ç¼Ç¿¡ ´ëÇÑ Å« ¼ö¿ä°¡ ¹ß»ýÇϰí ÀÖ½À´Ï´Ù.

ºÐÀÚÁø´ÜÀÇ ±â¼úÀû Áøº¸, ƯÈ÷ ½Ç½Ã°£ PCR°ú Â÷¼¼´ë ½ÃÄö½Ì ±â¼úÀº ±âÁ¸ °Ë»ç¹ý¿¡ ºñÇØ ¿ì¼öÇÑ ¹Î°¨µµ¿Í ƯÀ̼º, ºü¸¥ ³³±â¸¦ Á¦°øÇÔÀ¸·Î½á Áß¿äÇÑ ¼ºÀåÀÇ ±âÆøÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ¼ºº´¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ¿¹¹æÀÇÇп¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ö¿ä¸¦ ´õ¿í ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÷´Ü ºÐÀÚÁø´Ü Àåºñ ¹× °Ë»ç ÀýÂ÷¿¡ µû¸¥ ³ôÀº ºñ¿ë µî ½ÃÀå ÁøÀÔÀ庮ÀÌ ³ô¾Æ ÀÚ¿øÀÌ Á¦ÇÑµÈ ÀÇ·á ȯ°æ¿¡¼­ÀÇ È°¿ëÀÌ Á¦Çѵǰí ÀÖ´Â ½ÇÁ¤ÀÔ´Ï´Ù. ¶ÇÇÑ, HSV °Ë»ç¿Í °ü·ÃµÈ »çȸÀû ³«ÀÎÀÌ ½É¸®Àû À庮ÀÌ µÇ¾î Áø´Ü ¼­ºñ½º¸¦ ¹ÞÀ¸·Á´Â °³ÀÎÀÇ ÀÇ¿åÀ» ¶³¾î¶ß·Á ½ÃÀå ¼ºÀåÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. º¹ÀâÇÑ ±ÔÁ¦¿Í »õ·Î¿î Áø´Ü¾àÀÇ ½ÂÀο¡ °É¸®´Â ½Ã°£µµ Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» µµÀÔÇÏ·Á´Â ½ÃÀå °ü°èÀڵ鿡°Ô µµÀüÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦¾à¿¡µµ ºÒ±¸Çϰí, Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î °Ë»ç ±â´ÉÀÇ È®´ë, ÇÁ¶óÀ̹ö½Ã¿Í ÆíÀǼºÀ» Á¦°øÇÏ´Â ÀçÅà °Ë»ç ŰƮÀÇ Ã¤Åà Ȯ´ë, ÇコÄɾî ÀÎÇÁ¶ó°¡ °³¼±µÇ°í ÀÖ´Â ½ÅÈï ½ÃÀå¿¡¼­ÀÇ º¸±Þ È®´ë µîÀº Å« ºñÁî´Ï½º ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. Áø´Ü Ç÷§Æû¿¡ ÀΰøÁö´É°ú ¸Ó½Å·¯´×ÀÇ ÅëÇÕÀº Á¤È®µµ Çâ»ó°ú °á°ú ÀÚµ¿ ÇØ¼®ÀÇ ±âȸ¸¦ Á¦°øÇϰí, Áø´Ü ±â¾÷°ú ¿ø°Ý ÀÇ·á Ç÷§ÆûÀÇ Á¦ÈÞ´Â »õ·Î¿î À¯Åë ä³ÎÀ» âÃâÇϰí, ÀÇ·á ¼­ºñ½º¸¦ ¹ÞÁö ¸øÇÏ´Â »ç¶÷µéÀÇ °Ë»ç Á¢±Ù¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ HSV °Ë»ç ½ÃÀå, HSV À¯Çüº°, 2020-2032³â(100¸¸ ´Þ·¯)

Á¦5Àå ¼¼°èÀÇ HSV °Ë»ç ½ÃÀå, À¯Çüº°, 2020-2032³â

Á¦6Àå ¼¼°èÀÇ HSV °Ë»ç ½ÃÀå, »ùÇà À¯Çüº°, 2020-2032³â

Á¦7Àå ¼¼°èÀÇ HSV °Ë»ç ½ÃÀå, ¿¬·ÉÃþº°, 2020-2032³â

Á¦8Àå ¼¼°èÀÇ HSV °Ë»ç ½ÃÀå, ¿ëµµº°, 2020-2032³â

Á¦9Àå ¼¼°èÀÇ HSV °Ë»ç ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020-2032³â

Á¦10Àå ¼¼°èÀÇ HSV °Ë»ç ½ÃÀå, Áö¿ªº°, 2020-2032³â, °¡Ä¡

Á¦11Àå °æÀï ±¸µµ

Á¦12Àå ¾Ö³Î¸®½ºÆ® Ãßõ »çÇ×

Á¦13Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

HSV Testing Market is estimated to be valued at USD 642.4 Mn in 2025 and is expected to reach USD 972.3 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.1% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 642.4 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 6.10% 2032 Value Projection: USD 972.3 Mn

The global HSV testing market represents a critical segment within the broader diagnostic testing industry, focusing on the detection and identification of Herpes Simplex Virus infections that affect millions of individuals worldwide. HSV testing encompasses various diagnostic methodologies including PCR-based assays, antigen detection tests, antibody-based serological tests, and viral culture techniques, each designed to identify HSV-1 and HSV-2 infections with varying degrees of sensitivity and specificity.

The market's significance has grown substantially, due to increasing awareness about sexually transmitted infections, rising prevalence of herpes infections globally, and the growing emphasis on early diagnosis and treatment intervention. Healthcare providers, clinical laboratories, and point-of-care testing facilities constitute the primary end-users driving demand for HSV testing solutions. The market landscape is characterized by continuous technological advancements, including the development of rapid diagnostic tests, molecular diagnostics with enhanced accuracy, and automated testing platforms that improve workflow efficiency. Additionally, the integration of digital health solutions and telemedicine platforms has created new avenues for HSV testing accessibility, particularly in remote and underserved regions. The market's evolution is further influenced by regulatory approvals for novel testing methodologies, increasing healthcare expenditure, and growing patient preference for confidential and convenient testing options.

Market Dynamics

The global HSV testing market is propelled by several key drivers that collectively enhance market expansion and adoption rates across diverse healthcare settings. The primary driver stems from the escalating global prevalence of herpes simplex virus infections, with WHO estimates indicating that over 3.7 billion people under age 50 have HSV-1 infection and 491 million people aged 15-49 have HSV-2 infection worldwide, creating substantial demand for accurate diagnostic solutions.

Technological advancements in molecular diagnostics, particularly real-time PCR and next-generation sequencing techniques, serve as significant growth catalysts by offering superior sensitivity, specificity, and rapid turnaround times compared to traditional testing methods. Increasing awareness campaigns about sexually transmitted infections and growing emphasis on preventive healthcare measures further stimulate market demand. However, the market faces notable restraints including high costs associated with advanced molecular diagnostic equipment and testing procedures, which limit accessibility in resource-constrained healthcare settings. Additionally, social stigma associated with HSV testing creates psychological barriers that discourage individuals from seeking diagnostic services, potentially limiting market growth. Regulatory complexities and lengthy approval processes for new diagnostic products also pose challenges for market players seeking to introduce innovative solutions. Despite these constraints, significant opportunities emerge from expanding point-of-care testing capabilities, increasing adoption of home-based testing kits that offer privacy and convenience, and growing penetration in emerging markets with improving healthcare infrastructure. The integration of artificial intelligence and machine learning in diagnostic platforms presents opportunities for enhanced accuracy and automated result interpretation, while partnerships between diagnostic companies and telemedicine platforms create new distribution channels and improve testing accessibility in underserved populations.

Key features of the study

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global HSV Testing Market, By HSV Type, 2020-2032, (USD Mn)

5. Global HSV Testing Market, By Type, 2020-2032, (USD Mn)

6. Global HSV Testing Market, By Sample Type, 2020-2032, (USD Mn)

7. Global HSV Testing Market, By Age Group, 2020-2032, (USD Mn)

8. Global HSV Testing Market, By Application, 2020-2032, (USD Mn)

9. Global HSV Testing Market, By End User, 2020-2032, (USD Mn)

10. Global HSV Testing Market, By Region, 2020 - 2032, Value (USD Mn)

11. Competitive Landscape

12. Analyst Recommendations

13. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â